预防性腹腔镜肠系膜上静脉(No.14v)淋巴结清扫对胃下部癌的安全性与预后影响:倾向性评分匹配病例对照研究
该回顾性研究纳入757例接受腹腔镜辅助远端胃切除术的胃下部癌患者,其中102例接受14v淋巴结清扫。经1:1倾向性评分匹配后各93例比较,匹配后14vD+组总生存期优于14vD-组(P=0.025),分层分析显示cT2-3患者获益更明显,且14v清扫安全性可接受。
要点
- 腹腔镜14v淋巴结清扫用于胃下部癌安全可行。
- 匹配后14vD+组总生存期优于14vD-组(P=0.025)。
- cT2-3患者匹配后14vD+组3年OS率显著更高。
核心结论
- 在腹腔镜辅助远端胃根治术中加行14v淋巴结清扫安全,且可能改善无浆膜侵犯的临床进展期胃下部癌的总生存期。
研究设计与样本
- 回顾性收集757例因胃下部癌行腹腔镜辅助远端胃切除术的患者资料,其中14vD+组102例、14vD-组655例,采用1:1倾向性评分匹配比较结局。
主要发现
- 匹配后14vD+组与14vD-组各93例,临床病理特征相似。
- 匹配前两组总生存期相似(P=0.742),匹配后14vD+组总生存期更高(P=0.025)。
- 14v清扫状态在匹配前后生存分析中均非显著预后因素。
- 按OS独立因素分层分析,匹配后cT2-3患者中14vD+组OS高于14vD-组。
- 匹配后cT2-3患者中14vD+组3年OS率显著高于14vD-组,14v淋巴结的治疗指数与No.1、7、8a、9、11p相似。
临床怎么用
- 对无浆膜侵犯的临床进展期胃下部癌,可考虑在腹腔镜辅助远端胃根治术中加行14v淋巴结清扫。
局限性
- 本研究为单中心回顾性设计,结论需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To investigate oncologic efficacy of prophylactic laparoscopic superior mesenteric vein (No. 14v) lymph node (LN) dissection for lower-third gastric cancer (LTGC). METHODS: We retrospectively collected data from 757 patients who underwent laparoscopic-assisted distal gastrectomy for LTGC. Of these patients, 102 underwent 14v LN dissection (14vD+ group), and the remaining 655 patients did not undergo 14v LN dissection (14vD- group). The outcomes were compared using a 1:1 propensity score matching method. RESULTS: After matching, 93 patients from the 14vD+ group and 93 patients from the 14vD- group with similar clinicopathological characteristics were compared. Before matching, the overall survival (OS) was similar between the two groups (P = 0.742). After matching, the OS was greater in the 14vD+ group (P = 0.025). The status of 14v dissection was not a significant prognostic factor in the survival analyses, both before and after matching. However, a stratified analysis according to the independent factors in the OS showed that the OS in the 14vD+ group was higher than that in the 14vD- group for cT2-3 patients after matching. The forest plot of OS showed that after matching the 14vD+ group had a significantly higher 3-year OS rate than the 14vD- group in cT2-3 patients. The distribution of the therapeutic index demonstrated that the index of 14v LN was similar to those of Nos. 1, 7, 8a, 9, and 11p after matching. CONCLUSIONS: Adding laparoscopic 14v dissection for laparoscopic-assisted radical distal gastrectomy was safe and might improve the OS for clinically advanced LTGC without serosal invasion.
引用
- Chen QY, Zheng CH, Li P, et al. Safety and prognostic impact of prophylactic laparoscopic superior mesenteric vein (No. 14v) lymph node dissection for lower-third gastric cancer: a propensity score-matched case-control study. Surg Endosc. 2017. PMID: 28916893. doi:10.1007/s00464-017-5837-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。